Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

Summary

The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. following an overnight fast of at least 10 hours.

Timeline

Start

2006-10

Primary completion

2006-10

Completion

2006-10

Drugs

Indications

No indication recorded.